Biomea Fusion (BMEA) Other Working Capital Changes (2021 - 2026)
Biomea Fusion (BMEA) posted Other Working Capital Changes of -$350000.0 for Q1 2026, down 24.11% sequentially from -$282000.0 in Q4 2025, and up 58.53% YoY from -$220777.3 in Q1 2025.
Biomea Fusion (BMEA) Other Working Capital Changes (2021 - 2026) Analysis & Trends
Biomea Fusion has reported Other Working Capital Changes for 6 years, with the latest figure at -$350000.0 in Q1 2026.
- Quarterly Other Working Capital Changes rose 58.53% year-over-year to -$350000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.7 million (up 40.82% YoY) and the FY2025 annual result came in at -$2.2 million, down 45.04% from the prior year.
- Other Working Capital Changes eased to -$350000.0 in Q1 2026 per BMEA's latest filing, from -$282000.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $4.4 million in Q4 2024 and troughed at -$5.6 million in Q3 2025.
- A 5-year average of -$106588.2 and a median of $25000.0 in 2022 frame the typical range for Other Working Capital Changes.
- The sharpest annual moves came in 2023 and 2024: Other Working Capital Changes tumbled 343.06% in 2023, then jumped 186.78% in 2024.
- Over 5 years, Other Working Capital Changes stood at -$146000.0 in 2022, then tumbled by 179.45% to -$408000.0 in 2023, then slumped by 94.85% to -$795000.0 in 2024, then soared by 64.53% to -$282000.0 in 2025, then retreated by 24.11% to -$350000.0 in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$350000.0, -$282000.0, and -$177000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -362,000.00 |
| Jun 30, 2026 | -362,000.00 |
| Jun 30, 2026 | -362,000.00 |
| Mar 31, 2026 | -350,000.00 |
| Mar 31, 2026 | -350,000.00 |
| Mar 31, 2026 | -350,000.00 |
| Dec 31, 2025 | -282,000.00 |
| Dec 31, 2025 | -282,000.00 |
| Dec 31, 2025 | -282,000.00 |
| Sep 30, 2025 | -177,000.00 |
| Sep 30, 2025 | -177,000.00 |
| Sep 30, 2025 | -177,000.00 |
| Jun 30, 2025 | -874,000.00 |
| Jun 30, 2025 | -874,000.00 |
| Jun 30, 2025 | -874,000.00 |
| Mar 31, 2025 | -844,000.00 |
| Mar 31, 2025 | -844,000.00 |
| Mar 31, 2025 | -844,000.00 |
| Dec 31, 2024 | -795,000.00 |
| Dec 31, 2024 | -795,000.00 |